Glycated Albumin Assay

Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the glycated albumin assay market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[192 Pages Report] The Glycated Albumin Assay Market size was estimated at USD 217.29 million in 2023 and expected to reach USD 232.69 million in 2024, at a CAGR 7.51% to reach USD 360.92 million by 2030.

Glycated Albumin Assay Market
To learn more about this report, request a free PDF copy

The glycated albumin assay is a diagnostic test used to measure the amount of glycated albumin in the blood. Glycated albumin is a form of albumin, which is an abundant protein in human blood plasma and has bonded with glucose. It facilitates rapid adjustments in diabetes management strategies, potentially leading to better short-term control of blood glucose levels. It offers an alternative for people for whom HbA1c tests might not be accurate, such as those with hemoglobinopathies, recent blood transfusion recipients, or individuals with chronic kidney or liver diseases. The prevalence of diabetes and rising public awareness about monitoring and controlling blood glucose necessitates accurate and reliable testing methods. However, various countries' reimbursement policies and regulatory frameworks may hinder the widespread use of glycated albumin assays. Expanding healthcare infrastructure in emerging economies provides more significant access to advanced diagnostics tools such as glycated albumin assays, and research into novel biomarkers for glucose regulation is expected to create opportunities for growth of the glycated albumin assay market.

Glycated Albumin Assay Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Product: Increasing use of animal glycated albumin assay to understand disease mechanisms

The animal glycated albumin assay measures glycated albumin levels in animal samples, such as rodents. It is a critical tool for researchers studying diabetes and other related metabolic disorders in these species. This assay offers valuable insights into the efficacy of potential treatments and drug development. The human glycated albumin assay measures glycated albumin levels in human biological samples such as serum or plasma. This assay provides valuable diagnostic information on patients with diabetes by assessing their long-term blood glucose control.

Application: Significant adoption of glycated albumin assay for detection of type 1 diabetes owing to prevent health complications

The glycated albumin assay plays a vital role for individuals identified as prediabetic, indicating higher than normal blood glucose levels, which are not high enough to be classified as diabetes. In context, the assay can help monitor short-term changes in glucose levels, providing valuable information that can guide interventions to prevent the progression of type 2 diabetes. Prediabetic individuals can benefit from understanding the way their lifestyle changes, such as diet and exercise, immediately impact their blood glucose levels, making glycated albumin a helpful tool in preventive health strategies. Monitoring and managing blood glucose levels is a continuous necessity in individuals with type 1 diabetes, characterized by the autoimmune collapse of insulin-producing beta cells of the pancreas. The primary long-term monitoring tool remains the Hemoglobin A1c test; however, the glycated albumin assay is a vital complementary tool. Its faster turnover rate can be particularly beneficial in adjusting treatment regimens and providing a more immediate reflection of changes in blood glucose levels. Glycated albumin assay holds significant relevance for patients with Type 2 diabetes, ranking at the top in terms of application. This condition, characterized by insulin resistance and relative insulin deficiency, requires rigorous monitoring of blood glucose levels over various intervals. Glycated albumin provides a unique advantage as it reflects average glucose levels over a shorter period (approximately 2-4 weeks) than other markers. This allows for more immediate feedback on the effectiveness of dietary, lifestyle changes, or medication adjustments, making it exceptionally useful in managing type 2 diabetes.

End User: High usage of glycated albumin assay in diagnostic laboratories

Diabetic care centers are specialized centers focused primarily on managing diabetes and its associated complications. Glycated albumin assays are essential for evaluating medium-term glucose control in these centers, allowing for tailored dietary, lifestyle, and pharmacological interventions. Diabetic care centers are ranked below hospitals and clinics as they are more specialized and may not cater to as broad a patient base. Diagnostic laboratories serve as processing centers for samples collected from various healthcare facilities, including hospitals, clinics, and diabetic care centers. They play a crucial role in analyzing and reporting glycated albumin levels; however, their direct engagement with patients is less than that of the first two settings. Diagnostic laboratories support the healthcare ecosystem by providing accurate and timely results, which is essential for effective diabetes management. Hospitals and clinics represent the primary setting where glycated albumin assays are utilized to cater to a broad spectrum of patients, including a significant number of diabetic patients requiring continuous monitoring and management of their condition. Hospitals and clinics have laboratories that can promptly process glycated albumin tests, ensuring clinicians receive timely information to adjust treatment plans as necessary. Furthermore, during hospital admissions for complications, the need for close monitoring of diabetes control becomes crucial, underscoring the importance of glycated albumin assays in these settings.

Regional Insights

The Americas represents a significant landscape in the glycated albumin assay market owing to a substantial need for glycated albumin assay due to the high prevalence of diabetes in these countries. Additionally, countries have advanced healthcare systems that can support the adoption of innovative diagnostic tools such as glycated albumin assays. The growing aging population in Europe contributes significantly to the increasing need for advanced diagnostics such as glycated albumin assays. EU countries have comprehensive healthcare systems that prioritize early detection of diseases such as diabetes, increasing the glycated albumin assay need in the region. In the Middle East and Africa region, there has been a steady rise in lifestyle-related diseases, including diabetes, due to changing demographics and urbanization. Various programs, initiatives, and investments by legal authorities promoted the adoption of innovative diagnostic techniques in the region. The Asia-Pacific market for glycated albumin assay is expanding rapidly due to the growing prevalence of diabetes, increasing research and development activities, and significant advancements in developing novel techniques for glycated albumin detection.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Glycated Albumin Assay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Glycated Albumin Assay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Pioneering Partnership Between John Lewis and Randox Unveils In-Store Blood Testing to Enhance Health Diagnostics

    John Lewis joined forces with the diagnostic innovator Randox to introduce in-store blood testing services, marking a significant leap towards convenience in health and wellness. This collaboration, the first in department stores, aims to diminish NHS waiting lists by offering comprehensive health checks for various cancers, diabetes, and heart disease. Leveraging Randox's cutting-edge lab-on-a-chip technology, the partnership seeks to revolutionize cancer diagnostics, potentially reducing invasive procedures and alleviating NHS burdens with savings projected to be around GBP 3 billion annually. This service expansion into genetic testing and checks for vitamin deficiencies underlines a move toward personalized, preventative care. [Published On: 2024-02-26]

  • Strategic Initiatives to Combat Diabetes and Hypertension in India

    The West Bengal State Health Department announced efforts to manage diabetes and hypertension. To incorporate 7.5 million adults into standardized medical care by 2025, the initiative aims to reverse the oversight of these conditions during the COVID-19 pandemic. Specifically, Kolkata seeks to extend care to over 400,000 patients by December 2025. This nationwide campaign involves comprehensive screening efforts, early diagnosis, and timely intervention strategies, particularly targeting adults above 30 through free blood pressure and glucose screenings. These screenings are available at hospitals and community camps, with display signs at critical hospital locations such as OPD ticket counters, encouraging participation. [Published On: 2024-02-24]

  • Advancing Type 1 Diabetes Care: Enable Biosciences Launches Innovative 'Kit to Clinics' Program Featuring ADAP Technology

    Enable Biosciences Inc. rolled out its Kit to Clinics program tailored for type 1 diabetes care, harnessing cutting-edge Antibody Detection by Agglutination-PCR (ADAP) technology. This initiative aimed to transform early diabetes detection and management by providing clinics with a highly reliable testing tool, proven through rigorous, peer-reviewed studies, including impressive outcomes in the Islet Autoantibody Standardization Program evaluations. Endorsed by JDRF, the global player in type 1 diabetes research funding, this program underlines the significance of early diagnosis in leveraging new treatment advancements that can delay diabetes onset. [Published On: 2024-01-23]

Key Company Profiles

The report delves into recent significant developments in the Glycated Albumin Assay Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abcam PLC, Abnova Corporation, AFG Bioscience LLC, Asahi Kasei Corporation, Beijing Jiuqiang Biotechnology Co., Ltd., Biomatik Corporation, Cardinal Health, Inc., Crystal Chem Inc., Cusabio Technology LLC, Diazyme Laboratories, Inc., DxGen Corp., EKF Diagnostics Holdings by IBL PLC, Epinex Diagnostics Inc., Hzymes Biotech, Laboratory Corporation of America Holdings, LifeSpan BioSciences, Inc., Merck KGaA, Novatein Biosciences Inc., Sekisui Chemical Co., Ltd., Thermo Fisher Scientific Inc., Thomas Scientific LLC, Weldon Biotech, Inc., and Wuhan Fine Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Glycated Albumin Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Animal Glycated Albumin Assay
    • Human Glycated Albumin Assay
  • Application
    • Prediabetes
    • Type 1 Diabetes
    • Type 2 Diabetes
  • End User
    • Diabetic Care Centres
    • Diagnostic Laboratories
    • Hospitals & Clinics

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Glycated Albumin Assay Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Glycated Albumin Assay Market?
  3. What are the technology trends and regulatory frameworks in the Glycated Albumin Assay Market?
  4. What is the market share of the leading vendors in the Glycated Albumin Assay Market?
  5. Which modes and strategic moves are suitable for entering the Glycated Albumin Assay Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Glycated Albumin Assay Market, by Product
  7. Glycated Albumin Assay Market, by Application
  8. Glycated Albumin Assay Market, by End User
  9. Americas Glycated Albumin Assay Market
  10. Asia-Pacific Glycated Albumin Assay Market
  11. Europe, Middle East & Africa Glycated Albumin Assay Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 284]
  16. List of Companies Mentioned [Total: 24]
Understanding Glycated Albumin Assay: A Game Changer in Diabetes Diagnosis
October 13, 2023
Understanding Glycated Albumin Assay: A Game Changer in Diabetes Diagnosis
Diabetes is one of the most pressing health challenges of the 21st century. The increasing prevalence of diabetes worldwide has resulted in a growing need for better and more precise diagnostic tools to help healthcare professionals diagnose and manage the condition more effectively. One such tool that has emerged recently is the glycated albumin assay. This blog explores this game-changing diagnostic tool and how it can revolutionize the diagnosis and management of diabetes.

What is Glycated Albumin Assay?

Glycated albumin assay is a laboratory test that is used to measure the levels of glycated albumin, a protein molecule in blood that is formed after glucose attaches to albumin. It helps in evaluating the average blood sugar levels over a period of two weeks to a month. Unlike other diabetes tests, such as the HbA1c test, which can provide an average of blood sugar levels over three months, the glycated albumin assay can give a much more accurate and precise analysis of blood sugar fluctuations.

How does it work?

The glycated albumin assay uses a small sample of blood collected from a patient, which is then analyzed for the presence of glycated albumin. The test is based on the principle of highly sensitive fluorescence quenching immunoassay, which allows for the precise detection and measurement of glycated albumin. Healthcare professionals then use the test results to diagnose or monitor diabetes in patients.

Benefits of Glycated Albumin Assay:

The glycated albumin assay offers several benefits over traditional diabetes tests, such as the HbA1c test. Here are some of the key benefits:

Accurate and precise: The test is highly sensitive and allows for a more accurate and specific diagnosis of diabetes, especially in patients with kidney disease or hemoglobinopathies.
Early detection: The test can help detect diabetes at an early stage, enabling prompt and effective treatment to prevent the condition's progression.
Better management: The test can help healthcare professionals better manage diabetes patients by providing more precise data on glycemic control, allowing for tailored treatment plans to improve the patient's quality of life.


While glycated albumin assay has several benefits, there are also some limitations. Some of the key limitations include:

Cost: The test can be relatively expensive compared to other diabetes tests, making it inaccessible to low-income patients.
Availability: The test is not widely available in all healthcare settings and may not be covered by insurance companies.
Interpretation: The results of the test may require clinicians to get additional training, making it a less practical option for some healthcare providers.

The glycated albumin assay is an emerging diagnostic tool that has the potential to revolutionize the diagnosis and management of diabetes. It offers several benefits over traditional diagnostic tests, including increased accuracy, early detection, and better management of diabetes patients. However, some limitations, including cost, availability, and interpretation of results, need to be considered. Nevertheless, glycated albumin assay is a promising tool that can help provide more precise and tailored care to diabetes patients, leading to better health outcomes and improved quality of life.

Frequently Asked Questions
  1. How big is the Glycated Albumin Assay Market?
    Ans. The Global Glycated Albumin Assay Market size was estimated at USD 217.29 million in 2023 and expected to reach USD 232.69 million in 2024.
  2. What is the Glycated Albumin Assay Market growth?
    Ans. The Global Glycated Albumin Assay Market to grow USD 360.92 million by 2030, at a CAGR of 7.51%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.